Identification of a Notch transcriptomic signature for breast cancer

被引:1
|
作者
Braune, Eike-Benjamin [1 ]
Geist, Felix [2 ]
Tang, Xiaojia [3 ]
Kalari, Krishna [3 ]
Boughey, Judy [4 ]
Wang, Liewei [5 ]
Leon-Ferre, Roberto A. [6 ]
D'Assoro, Antonino B. [6 ]
Ingle, James N. [6 ]
Goetz, Matthew P. [5 ,6 ]
Kreis, Julian [2 ]
Wang, Kang [7 ]
Foukakis, Theodoros [7 ]
Seshire, Anita [8 ]
Wienke, Dirk [2 ]
Lendahl, Urban [1 ]
机构
[1] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden
[2] Merck Healthcare KGaA, Darmstadt, Germany
[3] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA
[4] Mayo Clin, Dept Surg, Rochester, MN USA
[5] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA
[6] Mayo Clin, Dept Oncol, Rochester, MN USA
[7] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[8] Merck KGaA, Darmstadt, Germany
关键词
Breast cancer; Basal-like; Breast cancer stem cell; Notch signalling; Transcriptomic signature; Therapy; Therapy resistance; Triple-negative; Diagnostics; GENE-EXPRESSION SIGNATURE; TUMOR-INITIATING CELLS; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; C-MYC; MAMMARY; DIFFERENTIATION; PROMOTES; TARGET; GROWTH;
D O I
10.1186/s13058-023-01757-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundDysregulated Notch signalling contributes to breast cancer development and progression, but validated tools to measure the level of Notch signalling in breast cancer subtypes and in response to systemic therapy are largely lacking. A transcriptomic signature of Notch signalling would be warranted, for example to monitor the effects of future Notch-targeting therapies and to learn whether altered Notch signalling is an off-target effect of current breast cancer therapies. In this report, we have established such a classifier.MethodsTo generate the signature, we first identified Notch-regulated genes from six basal-like breast cancer cell lines subjected to elevated or reduced Notch signalling by culturing on immobilized Notch ligand Jagged1 or blockade of Notch by gamma-secretase inhibitors, respectively. From this cadre of Notch-regulated genes, we developed candidate transcriptomic signatures that were trained on a breast cancer patient dataset (the TCGA-BRCA cohort) and a broader breast cancer cell line cohort and sought to validate in independent datasets.ResultsAn optimal 20-gene transcriptomic signature was selected. We validated the signature on two independent patient datasets (METABRIC and Oslo2), and it showed an improved coherence score and tumour specificity compared with previously published signatures. Furthermore, the signature score was particularly high for basal-like breast cancer, indicating an enhanced level of Notch signalling in this subtype. The signature score was increased after neoadjuvant treatment in the PROMIX and BEAUTY patient cohorts, and a lower signature score generally correlated with better clinical outcome.ConclusionsThe 20-gene transcriptional signature will be a valuable tool to evaluate the response of future Notch-targeting therapies for breast cancer, to learn about potential effects on Notch signalling from conventional breast cancer therapies and to better stratify patients for therapy considerations.
引用
收藏
页数:22
相关论文
共 50 条
  • [41] Notch, Myc and breast cancer
    Efstratiadis, Argiris
    Szabolcs, Matthias
    Klinakis, Apostolos
    [J]. CELL CYCLE, 2007, 6 (04) : 418 - 429
  • [42] NOTCH SIGNALING AND BREAST CANCER
    Reedijk, Michael
    [J]. NOTCH SIGNALING IN EMBRYOLOGY AND CANCER, 2012, 727 : 241 - 257
  • [43] Identification of drug-sensitive Notch receptor alterations in human breast cancer
    Wang, Kai
    Zhang, Qin
    Li, Danan
    Ching, Keith
    Zhang, Cathy
    Zheng, Xianxian
    Ozeck, Mark
    Shi, Stephanie
    Li, Xiaorong
    Wang, Hui
    Rejto, Paul
    Christensen, James
    Olson, Peter
    [J]. CANCER RESEARCH, 2015, 75 (22)
  • [44] Blood-based transcriptomic signature panel identification for cancer diagnosis: benchmarking of feature extraction methods
    Vijayan, Abhishek
    Fatima, Shadma
    Sowmya, Arcot
    Vafaee, Fatemeh
    [J]. BRIEFINGS IN BIOINFORMATICS, 2022, 23 (05)
  • [45] Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature
    Kohler, Katharina Theresa
    Goldhammer, Nadine
    Demharter, Samuel
    Pfisterer, Ulrich
    Khodosevich, Konstantin
    Ronnov-Jessen, Lone
    Petersen, Ole William
    Villadsen, Rene
    Kim, Jiyoung
    [J]. NPJ BREAST CANCER, 2022, 8 (01)
  • [46] Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature
    Katharina Theresa Kohler
    Nadine Goldhammer
    Samuel Demharter
    Ulrich Pfisterer
    Konstantin Khodosevich
    Lone Rønnov-Jessen
    Ole William Petersen
    René Villadsen
    Jiyoung Kim
    [J]. npj Breast Cancer, 8
  • [47] Identification of methylation sites and signature genes with prognostic value for luminal breast cancer
    Bin Xiao
    Lidan Chen
    Yongli Ke
    Jianfeng Hang
    Ling Cao
    Rong Zhang
    Weiyun Zhang
    Yang Liao
    Yang Gao
    Jianyun Chen
    Li Li
    Wenbo Hao
    Zhaohui Sun
    Linhai Li
    [J]. BMC Cancer, 18
  • [48] Identification of a three-gene signature in the triple-negative breast cancer
    Wang, Liping
    Luo, Zhou
    Sun, Minmin
    Yuan, Qiuyue
    Zou, Yinggang
    Fu, Deyuan
    [J]. BIOCELL, 2022, 46 (03) : 595 - 606
  • [49] Identification of upstream transcription factors (TFs) for expression signature genes in breast cancer
    Zang, Hongyan
    Li, Ning
    Pan, Yuling
    Hao, Jingguang
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2017, 33 (03) : 193 - 198
  • [50] Identification and Validation of an Autophagy-Related lncRNA Signature for Patients With Breast Cancer
    Zhang, Ruyue
    Zhu, Qingwen
    Yin, Detao
    Yang, Zhe
    Guo, Jinxiu
    Zhang, Jingmin
    Zhou, Yubing
    Yu, Jane J.
    [J]. FRONTIERS IN ONCOLOGY, 2021, 10